HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers
HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers
复制标题
DOI：
10.1097/01.aids.0000237363.33994.45
复制
发表时间：
2006-07-13
期刊：
影响因子：
3.8
通讯作者：
Lambert, John S.
中科院分区：
文献类型：
--
作者：
McFarland, Elizabeth J.;Johnson, Daniel C.;Lambert, John S.
目标：母乳传播仍然占全世界 HIV-1 母婴传播病例的很大一部分。有效的 HIV-1 疫苗与被动免疫或短期抗逆转录病毒预防相结合是预防母乳传播的潜在策略。本研究评估了 ALVAC HIV-1 疫苗在 HIV-1 感染妇女所生婴儿中使用和不使用亚单位包膜加强疫苗的安全性和免疫原性。设计：安慰剂对照、双盲研究。方法：使用金丝雀痘病毒 HIV-1 疫苗 (vCP1452) 和重组糖蛋白亚单位疫苗，对美国 HIV-1 感染母亲所生的婴儿进行初免加强方案免疫。 （rgp120）。婴儿 (n = 30) 被随机接受：单独使用 vCP1452、vCP1452 + rgp120 或相应的安慰剂。结果：局部反应为轻度或中度，未发生明显的全身毒性。接受两种疫苗的受试者具有与母源抗体不同的 gp120 特异性结合血清抗体。 75% 的患者观察到重复的 gp160 特异性淋巴增殖反应。在第 24 周时失去母体抗体的 vCP1452 + rgp-120 受试者中，有 50% 观察到与疫苗株同源的 HIV-1 中和活性。在一些婴儿中，HIV-1 特异性增殖和抗体反应持续到第 104 周。每个治疗组的两名受试者中检测到 HIV-1 特异性细胞毒性 T 淋巴细胞反应； HIV-1 特异性细胞毒性 T 淋巴细胞反应的频率在疫苗接受者和安慰剂接受者之间没有差异。结论：在婴儿早期疫苗诱导的免疫反应的证明支持进一步研究 HIV-1 疫苗接种作为减少母乳传播的策略。 (c) 2006 年利平科特·威廉姆斯和威尔金斯。
Objective: Breast milk transmission continues to account for a large proportion of cases of mother-to-child transmission of HIV-1 worldwide. An effective HIV-1 vaccine coupled with either passive immunization or short-term antiretroviral prophylaxis represents a potential strategy to prevent breast milk transmission. This study evaluated the safety and immunogenicity of ALVAC HIV-1 vaccine with and without a subunit envelope boost in infants born to HIV-1-infected women.Design: Placebo-controlled, double-blinded study.Methods: Infants born to HIV-1-infected mothers in the US were immunized with a prime-boost regimen using a canarypox virus HIV-1 vaccine (vCP1452) and a recombinant glycoprotein subunit vaccine (rgp120). Infants (n = 30) were randomized to receive: vCP1452 alone, vCP1452 + rgp120, or corresponding placebos.Results: Local reactions were mild or moderate and no significant systemic toxicities occurred. Subjects receiving both vaccines had gp120-specific binding serum antibodies that were distinguishable from maternal antibody. Repeated gp160-specific lymphoproliferative responses were observed in 75%. Neutralizing activity to HIV-1 homologous to the vaccine strain was observed in 50% of the vCP1452 + rgp-120 subjects who had lost maternal antibody by week 24. In some infants HIV-1-specific proliferative and antibody responses persisted until week 104. HIV-1-specific cytotoxic T lymphocyte responses were detected in two subjects in each treatment group; the frequency of HIV-1 specific cytotoxic T lymphocyte responses did not differ between vaccine and placebo recipients.Conclusion: The demonstration of vaccine-induced immune responses in early infancy supports further study of HIV-1 vaccination as a strategy to reduce breast milk transmission. (c) 2006 Lippincott Williams & Wilkins.